Floatz Rating
B63/100
Confidence
Indicative
Sponsor
SDK Therapeutics, Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07296445CT.gov A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301) | — | Not Yet Recruiting | — | — | — |
NCT00551460CT.gov S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | — | Completed | — | — | — |
NCT00528450CT.gov Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia | — | Terminated | — | — | — |
NCT00482833CT.gov Phase III Trial in Acute Promyelocytic Leukemia Patients | — | Completed | — | — | — |
NCT00454480CT.gov Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | — | Completed | — | — | — |
NCT00276601CT.gov Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia | — | Completed | — | — | — |
NCT00274781CT.gov Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes | — | Completed | — | — | — |
NCT00081133CT.gov Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00093483CT.gov Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00016159CT.gov Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia | — | Completed | — | — | — |
Show 9 more trialsShow fewer
NCT00006092CT.gov Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia | — | Terminated | — | — | — |
NCT00006008CT.gov Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00006090CT.gov Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia | — | Withdrawn | — | — | — |
NCT00020111CT.gov Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma | — | Completed | — | — | — |
NCT00005795CT.gov Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00006220CT.gov Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy | — | Terminated | — | — | — |
NCT00008697CT.gov Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia | — | Completed | — | — | — |
NCT00003395CT.gov Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer | — | Completed | — | — | — |
NCT00003885CT.gov Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Arsenic Trioxide (this asset) | SDK Therapeutics, Inc. | P3 | B · 63 |
| Vincristine Sulfate | Inhye Ahn | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BB |
| Pegaspargase | Dana-Farber Cancer Institute | P3 | BB |
| Idarubicin | Affiliated Hospital of Nantong University | P3 | BB |
| Nivestim | Hospital General de Mexico | P4 | BB |
| Thioguanine Anhydrous | Incyte Corporation | P3 | BB |
| Daunomycin | Richard Stone, MD | P3 | BB |
| Busulfanum | National Cancer Institute (NCI) | P4 | BB |
+42 more in the Leukemia cohort
Other indications for Arsenic Trioxide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | BBB · 79 |
| Plasma Cell Myeloma | — | P2 | BB · 71 |
| Central Nervous System Neoplasm | — | P2 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Arsenic Trioxide in Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/arsenic-trioxide-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →